Iovance Biotherapeutics, Inc.(IOVA)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

IOVA Iovance Biotherapeutics, Inc.

交易中 11-10 14:14:02 EST

7.99

-0.18

-2.20%

最高8.44	最低7.95	成交量601.46万
今开8.04	昨收8.17	日振幅6.00%
总市值36.97亿	流通市值33.75亿	总股本4.63亿
成交额4,906万	换手率1.42%	流通股本4.22亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"IOVA","market":"US","secType":"STK","nameCN":"Iovance Biotherapeutics, Inc.","latestPrice":7.99,"timestamp":1794338041941,"preClose":8.17,"halted":0,"volume":6014637,"delay":0,"changeRate":-0.022031823745410004,"floatShares":422406775,"shares":462655151,"eps":-0.508273,"marketStatus":"交易中","change":-0.18,"latestTime":"11-10 14:14:02 EST","open":8.04,"high":8.44,"low":7.95,"amount":49055265.093897,"amplitude":0.059976,"askPrice":7.99,"askSize":1000,"bidPrice":7.98,"bidSize":963,"shortable":3,"etf":0,"ttmEps":-0.508273,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1794344400000},"marketStatusCode":2,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":8.17,"preHourTrading":{"tag":"盘前","latestPrice":8.05,"preClose":8.17,"latestTime":"09:29 EST","volume":130022,"amount":1043002.938324,"timestamp":1794320999999,"change":-0.12,"changeRate":-0.014688,"amplitude":0.032974},"postHourTrading":{"tag":"盘后","latestPrice":8.22,"preClose":8.17,"latestTime":"19:56 EST","volume":886836,"amount":7351073.8437,"timestamp":1794272203017,"change":0.05,"changeRate":0.00612,"amplitude":0.026928},"volumeRatio":0.500611,"impliedVol":0.9258,"impliedVolPercentile":0.3187},"requestUrl":"/m/hq/s/IOVA","defaultTab":"news","newsList":[{"id":"1192931932","title":"异动解读｜Iovance Biotherapeutics, Inc.盘中上涨8.52%，财报超预期后市场重新交易商业化进展","url":"https://stock-news.laohu8.com/highlight/detail?id=1192931932","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1192931932?lang=zh_cn&edition=full","pubTime":"2026-11-09 23:47","pubTimestamp":1794239238,"startTime":"0","endTime":"0","summary":"11月9日，Iovance Biotherapeutics, Inc.盘中上涨8.52%，报8.725美元/股，成交额2848.61万美元。消息面上，公司近日披露第三季度每股亏损0.05美元，优于市场预期的亏损0.08至0.09美元；营收1.215亿美元，高于预期的约1.16亿美元，显示商业化放量与亏损收窄趋势延续。不过，公司全年产品收入指引仍维持在4.10亿至4.20亿美元，未在9月底大幅上调后进一步追加。短线股价走强，反映市场对业绩超预期本身的积极反馈。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"财报超预期亏损收窄，股价强势上涨","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IOVA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1123772176","title":"异动解读｜Iovance Biotherapeutics, Inc.盘中下跌8.22%，财报虽超预期但全年指引未再上修","url":"https://stock-news.laohu8.com/highlight/detail?id=1123772176","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1123772176?lang=zh_cn&edition=full","pubTime":"2026-11-06 01:02","pubTimestamp":1793898176,"startTime":"0","endTime":"0","summary":"11月6日，Iovance Biotherapeutics, Inc.盘中下跌8.22%，报7.985美元/股，成交额8567.83万美元。消息面上，公司最新披露第三季度每股亏损0.05美元，优于市场预期的亏损0.08至0.09美元；营收1.215亿美元，也高于预期的约1.16亿美元。不过，公司仅重申全年产品收入指引为4.10亿至4.20亿美元，未进一步上调。此前公司在9月末已将全年指引自3.50亿至3.70亿美元大幅提升至该区间，当前业绩利好兑现后，市场对后续增量预期转向谨慎。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"财报超预期却下跌，全年指引未再上调","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IOVA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1105638874","title":"异动解读｜Iovance Biotherapeutics, Inc.盘前上涨8.05%，瑞银上调目标价至8美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1105638874","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1105638874?lang=zh_cn&edition=full","pubTime":"2026-11-05 20:04","pubTimestamp":1793880298,"startTime":"0","endTime":"0","summary":"11月5日，Iovance Biotherapeutics, Inc.盘前上涨8.05%，报9.2594美元/股，成交额59.61万美元。消息面上，瑞银近日将公司目标价由7美元上调至8美元，并维持中性评级，带动短线情绪修复。从背景看，市场对公司整体看法仍偏积极，机构平均评级为overweight，平均目标价为14.30美元。Iovance Biotherapeutics, Inc.是一家新兴的生物技术公司，专注于培养细胞，使用自体肿瘤浸润淋巴细胞治疗转移性黑色素瘤等实体瘤的细胞治疗方法的发展和商业化。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"瑞银上调目标价，Iovance盘前上涨","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IOVA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1194349889","title":"异动解读｜Iovance Biotherapeutics, Inc.盘中上涨8.54%，瑞银上调目标价至8美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1194349889","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1194349889?lang=zh_cn&edition=full","pubTime":"2026-11-03 23:37","pubTimestamp":1793720224,"startTime":"0","endTime":"0","summary":"11月3日，Iovance Biotherapeutics, Inc.盘中上涨8.54%，报8.705美元/股，成交额3140.46万美元。消息面上，瑞银将公司目标价由7美元上调至8美元，并维持中性评级，带动市场情绪回暖。从背景看，机构对公司整体看法仍偏积极，FactSet统计显示其平均评级为overweight，平均目标价为14.30美元。公司将于11月5日披露季度业绩，市场预期当季营收约1.16亿美元、同比增长59.56%，调整后每股亏损收窄至0.09美元，交易焦点仍围绕Amtagvi商业化放量与亏损率改善。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"瑞银上调目标价，Iovance盘中上涨引关注","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IOVA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1107725529","title":"异动解读｜Iovance Biotherapeutics, Inc.盘中下跌8.08%，mNSCLC积极数据催化后股价继续回吐","url":"https://stock-news.laohu8.com/highlight/detail?id=1107725529","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1107725529?lang=zh_cn&edition=full","pubTime":"2026-11-02 23:43","pubTimestamp":1793634184,"startTime":"0","endTime":"0","summary":"11月2日，Iovance Biotherapeutics, Inc.盘中下跌8.08%，报7.795美元/股，成交额5020.44万美元。消息面上，公司此前围绕转移性非小细胞肺癌的TIL疗法积极数据及精准医疗策略进行说明，但相关利好在前序盘后、夜盘及盘前交易中已被资金充分交易，近期股价持续呈现利好兑现后的回吐走势。背景上，公司此前将全年营收指引上调至4.10亿至4.20亿美元，反映Amtagvi和Proleukin需求强劲；市场预计其下一季度营收约1.16亿美元，同比增长59.56%，调整后每股亏损有望收窄至0.09美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"利好兑现后，Iovance股价大幅回吐","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IOVA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1147629495","title":"异动解读｜Iovance Biotherapeutics, Inc.盘中下跌8.11%，mNSCLC积极数据催化后股价继续回吐","url":"https://stock-news.laohu8.com/highlight/detail?id=1147629495","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1147629495?lang=zh_cn&edition=full","pubTime":"2026-10-30 22:02","pubTimestamp":1793368954,"startTime":"0","endTime":"0","summary":"10月30日，Iovance Biotherapeutics, Inc.盘中下跌8.11%，报8.365美元/股，成交额5783.33万美元。消息面上，公司此前围绕转移性非小细胞肺癌的TIL疗法积极数据及精准医疗策略进行说明，但前一交易日盘后、夜盘及盘前连续走强后，盘中已出现利好兑现式回吐，当前弱势仍延续这一交易逻辑。背景上，公司此前将全年营收指引上调至4.10亿至4.20亿美元，反映Amtagvi和Proleukin需求强劲；市场预计其下季度营收约1.16亿美元，同比增长59.56%，调整后每股亏损有望收窄至0.09美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Iovance利好兑现回调，盘中走弱延续","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IOVA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1150327283","title":"异动解读｜Iovance Biotherapeutics, Inc.盘中下跌25.59%，mNSCLC积极数据催化后股价大幅回吐","url":"https://stock-news.laohu8.com/highlight/detail?id=1150327283","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1150327283?lang=zh_cn&edition=full","pubTime":"2026-10-29 21:38","pubTimestamp":1793281120,"startTime":"0","endTime":"0","summary":"10月29日，Iovance Biotherapeutics, Inc.盘中下跌25.59%，报11.4599美元/股，成交额1.6亿美元。消息面上，公司当日举行网络直播，介绍TIL疗法在转移性非小细胞肺癌中的积极数据及更广泛的精准医疗策略；但此前同题材已推动公司盘后、夜盘及盘前连续走强，本次盘中异动更体现为利好披露后的资金回吐。背景上，公司此前已将全年营收指引上调至4.10亿至4.20亿美元，反映Amtagvi和Proleukin需求强劲；市场预计其下一季度营收约1.16亿美元，同比增长59.56%，调整后每股亏损有望收窄至0.09美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Iovance盘中大跌，利好兑现资金回吐","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IOVA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1104268637","title":"异动解读｜Iovance Biotherapeutics, Inc.盘前上涨11.01%，公司将介绍mNSCLC积极数据及精准医疗策略","url":"https://stock-news.laohu8.com/highlight/detail?id=1104268637","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1104268637?lang=zh_cn&edition=full","pubTime":"2026-10-29 16:07","pubTimestamp":1793261263,"startTime":"0","endTime":"0","summary":"10月29日，Iovance Biotherapeutics, Inc.盘前上涨11.01%，报16.42美元/股，成交额19.49万美元。消息面上，公司宣布将于当日举行网络直播，介绍TIL疗法在转移性非小细胞肺癌中的积极数据及更广泛的精准医疗策略，成为本次异动的直接催化。同时，公司此前已将全年营收指引上调至4.10亿至4.20亿美元，反映Amtagvi和Proleukin需求强劲；市场一致预期其下一季度营收约1.16亿美元，同比增长59.56%，亏损亦有望继续收窄。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"盘前上涨，TIL疗法肺癌数据催化","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IOVA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1130349479","title":"财报前瞻 | Iovance Biotherapeutics, Inc.本季度营收预计增59.56%，机构观点偏乐观","url":"https://stock-news.laohu8.com/highlight/detail?id=1130349479","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1130349479?lang=zh_cn&edition=full","pubTime":"2026-10-29 11:18","pubTimestamp":1793243902,"startTime":"0","endTime":"0","summary":"Iovance Biotherapeutics, Inc.将于2026年11月05日发布最新季度财报，市场聚焦旗下首款商业化细胞疗法放量带来的盈利弹性与费用曲线变化。市场一致预期显示，本季度公司营收预计为1.16亿美元，同比增59.56%；毛利率预计为56.10%；净利率暂无一致预期；调整后每股收益预计为-0.09美元，同比改善66.91%；公司此前指引叠加渠道动销反馈显示，产品销售仍是收入主引擎。近期针对Iovance Biotherapeutics, Inc.的研报与评论中，看多观点占比更高，主线集中于商业化放量带动营收高增与亏损率持续收窄。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"财报前瞻 | Iovance Biotherapeutics, Inc.本季度营收预计增59.56%，机构观点偏乐观","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IOVA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1143383665","title":"异动解读｜Iovance Biotherapeutics, Inc.夜盘上涨9.93%，公司将介绍mNSCLC积极数据及精准医疗策略","url":"https://stock-news.laohu8.com/highlight/detail?id=1143383665","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1143383665?lang=zh_cn&edition=full","pubTime":"2026-10-29 08:00","pubTimestamp":1793232027,"startTime":"0","endTime":"0","summary":"10月29日，Iovance Biotherapeutics, Inc.夜盘上涨9.93%，报16.28美元/股，成交额407.0美元。消息面上，公司宣布将于当日举行网络直播，介绍TIL疗法在转移性非小细胞肺癌中的积极数据，以及更广泛的精准医疗策略，成为夜盘异动的直接催化。此前公司已在实体瘤TIL平台推进上持续释放积极进展，且于9月底将全年营收指引上调至4.10亿至4.20亿美元，反映Amtagvi和Proleukin需求强劲，业务放量预期与新适应症拓展共同提升市场关注度。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"IOVA夜盘大涨，TIL肺癌数据引关注","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IOVA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1164591010","title":"异动解读｜Iovance Biotherapeutics盘后上涨7.97%，公司将介绍mNSCLC积极数据及精准医疗策略","url":"https://stock-news.laohu8.com/highlight/detail?id=1164591010","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1164591010?lang=zh_cn&edition=full","pubTime":"2026-10-29 07:11","pubTimestamp":1793229062,"startTime":"0","endTime":"0","summary":"10月29日，Iovance Biotherapeutics盘后上涨7.97%，报15.98美元/股，成交额590.95万美元。消息面上，公司宣布将于当日举办网络直播，介绍TIL疗法在转移性非小细胞肺癌中的积极数据及更广泛的精准医疗策略，成为盘后异动的直接催化。业务放量预期与临床进展共同提升市场关注度。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Iovance盘后上涨，将公布肺癌积极数据","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IOVA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1188243809","title":"异动解读｜Iovance Biotherapeutics盘中上涨5.19%，将于11月5日公布第三季度业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=1188243809","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1188243809?lang=zh_cn&edition=full","pubTime":"2026-10-27 22:51","pubTimestamp":1793112665,"startTime":"0","endTime":"0","summary":"10月27日，Iovance Biotherapeutics盘中上涨5.19%，报14.495美元/股，成交额3864.33万美元。消息面上，公司宣布将于11月5日公布第三季度财务业绩及公司更新，成为当日股价异动的直接催化。此前公司在9月底已将全年营收指引上调至4.10亿至4.20亿美元，高于原先的3.50亿至3.70亿美元；同时，近期在ESMO大会披露的黑色素瘤2期试验最终分析显示，lifileucel联合pembrolizumab总体缓解率为62.5%，完全缓解率为29.2%。业绩预期与临床进展共同支撑市场关注度回升。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Iovance盘中上涨，三季度业绩即将揭晓","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IOVA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1128502373","title":"异动解读｜Iovance Biotherapeutics盘中下跌5.07%，ESMO黑色素瘤数据公布后股价继续回吐","url":"https://stock-news.laohu8.com/highlight/detail?id=1128502373","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1128502373?lang=zh_cn&edition=full","pubTime":"2026-10-26 22:45","pubTimestamp":1793025905,"startTime":"0","endTime":"0","summary":"10月26日，Iovance Biotherapeutics盘中下跌5.07%，报13.37美元/股，成交额4028.88万美元。不过，相关利好已在前期集中释放，且公司股价在9月底因上调全年营收指引至4.10亿至4.20亿美元后曾大幅走强，当前下跌更多体现为数据催化后的回吐。Iovance Biotherapeutics, Inc.是一家新兴的生物技术公司，专注于培养细胞，使用自体肿瘤浸润淋巴细胞治疗转移性黑色素瘤等实体瘤的细胞治疗方法的发展和商业化。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Iovance股价继续回吐，黑色素瘤数据利好出尽","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IOVA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1143608680","title":"异动解读｜Iovance Biotherapeutics盘中下跌5.13%，ESMO数据催化后股价回吐","url":"https://stock-news.laohu8.com/highlight/detail?id=1143608680","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1143608680?lang=zh_cn&edition=full","pubTime":"2026-10-23 00:50","pubTimestamp":1792687805,"startTime":"0","endTime":"0","summary":"10月23日，Iovance Biotherapeutics盘中下跌5.13%，报13.8美元/股，成交额6616.5万美元。近几日公司消息面主要集中于ESMO大会展示其跨实体瘤TIL细胞治疗平台，重点包括一线黑色素瘤及既往经治非小细胞肺癌中的深度、持久缓解数据。此前公司还在9月底将全年营收指引上调至4.10亿至4.20亿美元，高于原先的3.50亿至3.70亿美元，反映Amtagvi与Proleukin需求改善。此次股价走弱，发生在前期利好披露之后。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"ESMO数据催化后，Iovance股价回吐","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IOVA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1124804736","title":"异动解读｜Iovance Biotherapeutics盘中上涨5.36%，ESMO大会展示TIL疗法进展","url":"https://stock-news.laohu8.com/highlight/detail?id=1124804736","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1124804736?lang=zh_cn&edition=full","pubTime":"2026-10-19 21:40","pubTimestamp":1792417230,"startTime":"0","endTime":"0","summary":"10月19日，Iovance Biotherapeutics盘中上涨5.36%，报14.535美元/股，成交额1608.62万美元。消息面上，公司宣布将在欧洲肿瘤医学学会大会重点展示跨实体瘤TIL细胞治疗平台，并将以两场口头报告公布一线黑色素瘤及经治非小细胞肺癌中的深度、持久缓解数据，强化市场对其实体瘤细胞疗法商业化与适应症拓展前景的关注。公司此前还将全年营收指引上调至4.10亿至4.20亿美元，高于原先的3.50亿至3.70亿美元，显示Amtagvi与Proleukin需求改善，为此次股价异动提供基本面支撑。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Iovance股价上涨，TIL疗法进展引关注","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IOVA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1149716631","title":"异动解读｜Iovance Biotherapeutics盘中下跌5.54%，报13.9美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1149716631","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1149716631?lang=zh_cn&edition=full","pubTime":"2026-10-16 21:52","pubTimestamp":1792158722,"startTime":"0","endTime":"0","summary":"10月16日，Iovance Biotherapeutics盘中下跌5.54%，报13.9美元/股，成交额1651.33万美元。Iovance Biotherapeutics所在的生物科技行业中，Moderna, Inc.跌6.49%，艾伯维公司涨0.14%，安进涨0.43%，吉利德科学跌0.62%，福泰制药跌0.12%。公司专注于自体肿瘤浸润淋巴细胞（TIL）疗法的开发与商业化，核心方向包括转移性黑色素瘤等实体瘤治疗。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IOVA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1142850106","title":"异动解读｜Iovance Biotherapeutics盘中上涨5.62%，新任首席医疗官任命落地","url":"https://stock-news.laohu8.com/highlight/detail?id=1142850106","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1142850106?lang=zh_cn&edition=full","pubTime":"2026-10-09 22:01","pubTimestamp":1791554476,"startTime":"0","endTime":"0","summary":"10月9日，Iovance Biotherapeutics盘中上涨5.62%，报14.058美元/股，成交额3239.29万美元。消息面上，公司在10月1日宣布任命Noah Berkowitz博士为首席医疗官，该人事变动发生在大幅上调2026年营收指引、股价短期急涨之后，市场在经历回调后重新获得买盘支撑。Iovance Biotherapeutics, Inc.是一家新兴的生物技术公司，专注于培养细胞，使用自体肿瘤浸润淋巴细胞治疗转移性黑色素瘤等实体瘤的细胞治疗方法的发展和商业化。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Iovance任命新首席医疗官，股价盘中走高","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IOVA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1152230183","title":"异动解读｜Iovance Biotherapeutics盘中下跌5.27%，任命新任首席医疗官","url":"https://stock-news.laohu8.com/highlight/detail?id=1152230183","media":"行情直击","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1152230183?lang=zh_cn&edition=full","pubTime":"2026-10-06 22:07","pubTimestamp":1791295628,"startTime":"0","endTime":"0","summary":"10月6日，Iovance Biotherapeutics盘中下跌5.27%，报13.405美元/股，成交额4195.87万美元。消息面上，公司于10月1日宣布任命Noah Berkowitz医学博士为首席医疗官，该人事变动发生在公司大幅上调2026年营收指引、股价短期经历35%以上急涨之后，市场在连续上涨后出现回调。Iovance Biotherapeutics, Inc.是一家新兴的生物技术公司，专注于培养细胞，使用自体肿瘤浸润淋巴细胞治疗转移性黑色素瘤等实体瘤的细胞治疗方法的发展和商业化。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Iovance盘中回调，新首席医疗官上任","news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IOVA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1121733946","title":"异动解读｜Iovance Biotherapeutics盘中上涨18.29%，上调全年营收指引超市场预期","url":"https://stock-news.laohu8.com/highlight/detail?id=1121733946","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1121733946?lang=zh_cn&edition=full","pubTime":"2026-09-29 21:31","pubTimestamp":1790688687,"startTime":"0","endTime":"0","summary":"9月29日，Iovance Biotherapeutics盘中上涨18.29%，报12.96美元/股，成交额5088.31万美元。消息面上，公司最新上调全年营收指引，预计全年营收区间为4.1亿至4.2亿美元，较此前3.5亿至3.7亿美元的指引大幅提升，同时高于FactSet市场一致预期的4.028亿美元。Iovance Biotherapeutics是一家生物技术公司，专注于利用自体肿瘤浸润淋巴细胞开发和商业化针对转移性黑色素瘤等实体瘤的细胞治疗方法。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Iovance上调全年营收指引，股价强势上涨","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IOVA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1153460492","title":"异动解读｜Iovance Biotherapeutics盘前上涨8.46%，上调全年营收指引超市场预期","url":"https://stock-news.laohu8.com/highlight/detail?id=1153460492","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1153460492?lang=zh_cn&edition=full","pubTime":"2026-09-29 19:58","pubTimestamp":1790683127,"startTime":"0","endTime":"0","summary":"9月29日，Iovance Biotherapeutics盘前上涨8.46%，报11.94美元/股，成交额275.78万美元。消息面上，公司最新发布全年营收指引，预计全年营收区间为4.1亿至4.2亿美元，高于FactSet市场一致预期的4.028亿美元。此前公司二季度业绩已大幅超预期，营收约9930万美元创历史新高，每股亏损0.11美元优于市场预期的亏损0.13至0.14美元。Iovance Biotherapeutics是一家生物技术公司，专注于利用自体肿瘤浸润淋巴细胞开发和商业化针对转移性黑色素瘤等实体瘤的细胞治疗方法。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"上调全年营收指引，Iovance盘前上涨","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IOVA"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.iovance.com","stockEarnings":[{"period":"1week","weight":0.0187},{"period":"1month","weight":-0.4412},{"period":"3month","weight":0.2589},{"period":"6month","weight":1.2322},{"period":"1year","weight":2.5522},{"period":"ytd","weight":1.9927}],"compareEarnings":[{"period":"1week","weight":0.0008},{"period":"1month","weight":-0.0332},{"period":"3month","weight":-0.0232},{"period":"6month","weight":0.014},{"period":"1year","weight":0.1218},{"period":"ytd","weight":0.1038}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Iovance Biotherapeutics, Inc.是一家新兴的生物技术公司，专注于培养细胞，使用自体肿瘤浸润淋巴细胞（TIL）治疗转移性黑色素瘤等实体瘤的细胞治疗方法的发展和商业化。该公司于2007年9月17日在内华达州成立。","yearOnYearQuotes":[{"month":1,"riseRate":0.363636,"avgChangeRate":0.029113},{"month":2,"riseRate":0.545455,"avgChangeRate":0.158395},{"month":3,"riseRate":0.166667,"avgChangeRate":-0.048412},{"month":4,"riseRate":0.333333,"avgChangeRate":-0.016024},{"month":5,"riseRate":0.416667,"avgChangeRate":-0.065253},{"month":6,"riseRate":0.5,"avgChangeRate":0.132853},{"month":7,"riseRate":0.666667,"avgChangeRate":0.041289},{"month":8,"riseRate":0.416667,"avgChangeRate":0.083754},{"month":9,"riseRate":0.333333,"avgChangeRate":-0.004561},{"month":10,"riseRate":0.416667,"avgChangeRate":-0.055832},{"month":11,"riseRate":0.666667,"avgChangeRate":0.061716},{"month":12,"riseRate":0.636364,"avgChangeRate":0.051779}],"exchange":"NASDAQ","name":"Iovance Biotherapeutics, Inc.","nameEN":"Iovance Biotherapeutics, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.53.0","shortVersion":"4.53.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Iovance Biotherapeutics, Inc.(IOVA)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Iovance Biotherapeutics, Inc.(IOVA)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Iovance Biotherapeutics, Inc.,IOVA,Iovance Biotherapeutics, Inc.股票,Iovance Biotherapeutics, Inc.股票老虎,Iovance Biotherapeutics, Inc.股票老虎国际,Iovance Biotherapeutics, Inc.行情,Iovance Biotherapeutics, Inc.股票行情,Iovance Biotherapeutics, Inc.股价,Iovance Biotherapeutics, Inc.股市,Iovance Biotherapeutics, Inc.股票价格,Iovance Biotherapeutics, Inc.股票交易,Iovance Biotherapeutics, Inc.股票购买,Iovance Biotherapeutics, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Iovance Biotherapeutics, Inc.(IOVA)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Iovance Biotherapeutics, Inc.(IOVA)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}